We are live on ! Find out more
KERX

Keryx Biopharmaceuticals Inc
KERX

Delisted

KERX was delisted on the 12th of December, 2018.

123 hedge funds and large institutions have $399M invested in Keryx Biopharmaceuticals Inc in 2016 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 36 increasing their positions, 38 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 12

13% more capital invested

Capital invested by funds: $354M → $399M (+$44.8M)

6% more funds holding

Funds holding: 116123 (+7)

5% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 38

30% less call options, than puts

Call options by funds: $3.06M | Put options by funds: $4.37M

Holders
123
Holders Change
+7
Holders Change %
+6.03%
% of All Funds
3.07%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
19
Increased
36
Reduced
38
Closed
12
Calls
$3.06M
Puts
$4.37M
Net Calls
-$1.31M
Net Calls Change
-$776K
Name Holding Trade Value Shares
Change
Change in
Stake
OC
51
Oppenheimer & Co
New York
$407K +$19.7K +3,600 +5%
State Board of Administration of Florida Retirement System
52
State Board of Administration of Florida Retirement System
Florida
$380K
WMSA
53
Weiss Multi-Strategy Advisers
New York
$375K
MLICM
54
Metropolitan Life Insurance Company (MetLife)
New York
$375K +$21.8K +3,994 +7%
Wells Fargo
55
Wells Fargo
California
$358K +$139K +25,398 +71%
Deutsche Bank
56
Deutsche Bank
Germany
$353K -$570K -104,357 -63%
EAM
57
EverPoint Asset Management
Connecticut
$352K +$328K +60,000 New
Manulife (Manufacturers Life Insurance)
58
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$328K -$1.81K -331 -0.6%
Royal Bank of Canada
59
Royal Bank of Canada
Ontario, Canada
$328K +$306K +55,945 +65,052%
VFA
60
Virtus Fund Advisers
Connecticut
$327K
BG
61
BlackRock Group
United Kingdom
$324K +$30.4K +5,555 +11%
AIM
62
Advantage Investment Management
Iowa
$321K +$52.4K +9,596 +21%
Squarepoint
63
Squarepoint
New York
$309K +$288K +52,738 New
AG
64
Advisor Group
Arizona
$308K +$78.3K +14,335 +38%
Janney Montgomery Scott
65
Janney Montgomery Scott
Pennsylvania
$302K +$273 +50 +0.1%
NFA
66
Nationwide Fund Advisors
Ohio
$291K -$12.9K -2,370 -5%
Citadel Advisors
67
Citadel Advisors
Florida
$277K +$259K +47,309 New
WC
68
Woodstock Corp
Massachusetts
$276K -$52.3K -9,576 -17%
NFC
69
Northeast Financial Consultants
Connecticut
$270K
MIM
70
Marco Investment Management
Georgia
$266K -$21.9K -4,000 -8%
AIG
71
American International Group
New York
$266K -$645 -118 -0.3%
BA
72
BlackRock Advisors
Delaware
$261K -$6.05K -1,108 -2%
T. Rowe Price Associates
73
T. Rowe Price Associates
Maryland
$259K -$69.4K -12,700 -22%
BWP
74
Baldwin Wealth Partners
Massachusetts
$254K -$89.2K -16,325 -27%
UBS AM
75
UBS AM
Illinois
$224K -$194K -35,500 -48%

KERX Hedge Fund Activity: Q4 2016 in Review

123 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q4 2016, worth a combined $399M — up 13% from $354M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new KERX positions and 12 closed out — a net gain of 7 holders — while 36 added to existing stakes and 38 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $7.06M. The largest seller was Fidelity Investments, cutting an estimated $3.82M.

  • 123 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q4 2016, up from 116 in Q3 2016.
  • Funds reported $399M of Keryx Biopharmaceuticals Inc stock for Q4 2016, up 13% quarter-over-quarter.
  • 19 funds opened new Keryx Biopharmaceuticals Inc positions in Q4 2016 and 12 closed out, a net change of +7 holders.
  • The largest Keryx Biopharmaceuticals Inc buyer in Q4 2016 was Deerfield Management, an estimated $7.06M added.
  • The largest Keryx Biopharmaceuticals Inc seller in Q4 2016 was Fidelity Investments, an estimated $3.82M sold.

Based on aggregated 13F filings for Q4 2016.